Tumour Debulking and Reduction in Predicted Risk of Tumour Lysis Syndrome With Single-Agent Ibrutinib in Patients With Chronic Lymphocytic Leukaemia

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15791
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Tumour Lysis Syndrome After Treatment of Chronic Lymphocytic Leukaemia With Fludarabine.

Postgraduate Medical Journal
Medicine
1994English

Venetoclax‐induced Tumour Lysis Syndrome in Acute Myeloid Leukaemia

British Journal of Haematology
Hematology
2019English

Acute Respiratory Distress Syndrome Associated With Tumour Lysis Syndrome in Leukemia

Canadian Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1997English

Single Dose Rasburicase Is a Clinically Effective Pharmacoeconomic Approach for Preventing Tumour Lysis Syndrome in Children With High Tumour Burden

British Journal of Haematology
Hematology
2017English

An Assessment of a Short-Term Tumour Chemosensitivity Assay in Chronic Lymphocytic Leukaemia

British Journal of Cancer
Cancer ResearchOncology
1983English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib

British Journal of Haematology
Hematology
2017English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Autoimmune Cytopenias in Patients With Chronic Lymphocytic Leukaemia Treated With Ibrutinib in Routine Clinical Practice at an Academic Medical Centre

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy